NeuExo Therapeutics is a biotechnology company focused on developing exosome-based therapeutics for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company leverages natural extracellular vesicle (exosome) delivery systems to transport therapeutic cargo—including microRNAs, proteins, and small molecules—across the blood-brain barrier to target neurons affected by neurodegeneration.
| Attribute |
Details |
| Headquarters |
Cambridge, Massachusetts, USA |
| Founded |
2021 |
| Focus |
Exosome-based therapeutics for neurodegenerative disease |
| Lead Indication |
Parkinson's disease |
| Website |
https://www.neuexotherapeutics.com |
NeuExo has developed a proprietary platform for engineering therapeutic exosomes:
- Cargo Loading: Proprietary methods for loading exosomes with therapeutic molecules
- Targeting: Surface modification of exosomes for neuron-specific targeting
- Manufacturing: Scalable production of clinical-grade exosomes
- Quality Control: Standardized protocols for batch-to-batch consistency
Exosomes offer several advantages for CNS drug delivery:
- Blood-brain barrier penetration: Natural ability to cross the BBB
- Low immunogenicity: Reduced immune response compared to viral vectors
- Cellular targeting: Can be engineered to target specific neural cell types
- Cargo versatility: Can deliver proteins, RNAs, small molecules, and nucleotides
- Repeat dosing: Feasible due to favorable safety profile
NeuExo's lead program uses exosome-mediated delivery of miR-124 for Parkinson's disease:
- Mechanism: miR-124 is the most abundant miRNA in the brain and plays critical roles in neuronal survival. In PD, miR-124 expression is significantly reduced in dopaminergic neurons.
- Therapeutic rationale: Restoring miR-124 levels can promote neuronal survival, enhance autophagy and lysosomal function, and reduce neuroinflammation.
- Delivery: Exosomes provide natural delivery across the BBB to target neurons in the substantia nigra and striatum
- Stage: Preclinical development
The therapeutic approach is supported by peer-reviewed research:
- Exosome-mediated delivery of miR-124 has demonstrated neuroprotection in PD models
- miR-124 targets multiple pathways relevant to PD pathogenesis including UBE2A, BAX, and SCARB2
- Exosome biology provides natural mechanisms for CNS delivery
Additional programs in development include:
| Program |
Indication |
Modality |
Stage |
| miR-7 delivery |
Parkinson's disease |
miRNA (exosome) |
Discovery |
| GDNF delivery |
Parkinson's disease |
Protein (exosome) |
Discovery |
| Combination therapy |
PD (advanced) |
Multi-cargo exosome |
Research |
¶ Competitive Landscape
NeuExo operates in the emerging exosome therapeutics space for neurodegeneration:
| Company |
Approach |
Stage |
| NeuExo Therapeutics |
Exosome-miR-124 |
Preclinical |
| uniQure |
AAV gene therapy |
Phase 1/2 |
| Voyager Therapeutics |
AAV-AADC |
Phase 1 |
| RNP Inc |
RNA therapeutics (RNAi/ASO) |
Preclinical |
| Prothelia |
AAV-GBA gene therapy |
Preclinical |
- Exosome platform: Natural delivery system with inherent BBB penetration
- Focus on miR-124: Well-validated target with strong scientific support
- Combination potential: Platform enables multi-cargo delivery
- Manufacturing scalability: Established processes for clinical production
NeuExo maintains collaborations with academic centers for research and validation:
- Academic partnerships with leading neuroscience research institutions
- Collaboration with exosome biology researchers
- Engagement with PD patient advocacy organizations
NeuExo's development strategy includes:
- IND-enabling studies: Advance lead program toward clinical trial submission
- Manufacturing scale-up: Establish commercial-scale exosome production
- Pipeline expansion: Develop additional exosome-based programs for AD and ALS
- Strategic partnerships: Engage with pharmaceutical partners for co-development